Please assess the completion status of the following clinical trial:

Trial Title: Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cohort 1 (treatment-naive)~* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening~* Screening genotype report must show sensitivity to FTC and TDF~* No prior use of any approved or investigational antiretroviral drug for any length of time~Cohort 2 (treatment-experienced, pharmacoenhancer switch)~* Subjects must be receiving ATV 300 mg/ritonavir (RTV) 100 mg plus 2 NRTIs OR DRV 800 mg/RTV 100 mg plus 2 NRTIs for at least 6 months prior to screening~* Plasma HIV-1 RNA concentrations at undetectable levels in the 6 months preceding the screening visit and have HIV-1 RNA \< 50 copies/mL at screening~* Subjects experiencing intolerance to RTV (as determined by the investigator)~Both groups~* The ability to understand and sign a written informed consent form~* Normal ECG~* Mild to moderate renal function~* Stable renal function~* Hepatic transaminases (AST and ALT) ≤ 5 x the upper limit of the normal range (ULN)~* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin (subjects with documented Gilbert's Syndrome or hyperbilirubinemia due to atazanavir therapy may have total bilirubin up to 5 x ULN)~* Adequate hematologic function~* Serum amylase ≤ 5 x ULN~* Males and females of childbearing potential must agree to utilize highly effective contraception methods from screening throughout the duration of study treatment and for 30 days following the last dose of study drug~* Age ≥ 18 years~Exclusion Criteria:~* New AIDS-defining condition diagnosed within the 30 days prior to screening~* Receiving drug treatment for hepatitis C, or anticipated to receive treatment for hepatitis C~* Subjects experiencing decompensated cirrhosis~* Females who are breastfeeding~* Positive serum pregnancy test (female of childbearing potential)~* Implanted defibrillator or pacemaker~* Current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance~* History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline~* Receiving ongoing therapy with any of medications contraindicated for use with elvitegravir (EVG), COBI, FTC, TDF, ATV, DRV; or subjects with any known allergies to the excipients of E/C/F/TDF STR, COBI tablets, ATV capsules or DRV tablets or contraindicated for the 2 NRTIs as part of the PI/co regimen~* Participation in any other clinical trial without prior approval~* Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E/C/F/TDF (Cohort 1) (Type: EXPERIMENTAL): Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country.
- COBI+PI+2 NRTI (Cohort 2) (Type: EXPERIMENTAL): Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country.

Based on this trial design, predict the completion outcome and termination type (if applicable).